$190.60
1.23% day before yesterday
NYSE, Feb 07, 10:12 pm CET
ISIN
US00287Y1091
Symbol
ABBV
Sector
Industry

AbbVie Stock price

$190.60
+11.07 6.17% 1M
+3.09 1.65% 6M
+12.90 7.26% YTD
+15.59 8.91% 1Y
+48.07 33.73% 3Y
+98.31 106.52% 5Y
+135.12 243.55% 10Y
NYSE, Closing price Fri, Feb 07 2025
-2.37 1.23%
ISIN
US00287Y1091
Symbol
ABBV
Sector
Industry

Key metrics

Market capitalization $336.82b
P/E (TTM) P/E ratio 79.51
P/S ratio (TTM) P/S ratio 5.98
P/B ratio (TTM) P/B ratio 55.84
Dividend yield 3.30%
Last dividend (FY24) $6.29
Revenue growth (TTM) Revenue growth 3.71%
Revenue (TTM) Revenue $56.33b
EBIT (operating result TTM) EBIT $16.68b
Cash position $7.29b
EPS (TTM) EPS $2.40
P/E forward 51.63
P/S forward 5.54
EV/Sales forward 6.68
Short interest 1.03%
Show more

Is AbbVie a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,823 stocks worldwide.

AbbVie Stock Analysis

Unlock Scores for Free

Analyst Opinions

31 Analysts have issued a AbbVie forecast:

20x Buy
65%
11x Hold
35%

Analyst Opinions

31 Analysts have issued a AbbVie forecast:

Buy
65%
Hold
35%

Financial data from AbbVie

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
56,334 56,334
4% 4%
100%
- Direct Costs 14,974 14,974
7% 7%
27%
47,609 47,609
25% 25%
85%
- Selling and Administrative Expenses 16,367 16,367
830% 830%
29%
- Research and Development Expense 8,315 8,315
8% 8%
15%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT 16,678 16,678
17% 17%
30%
Net Profit 4,248 4,248
12% 12%
8%

In millions USD.

Don't miss a Thing! We will send you all news about AbbVie directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

AbbVie Stock News

Positive
The Motley Fool
about 15 hours ago
Dividend stocks are great for many reasons, not least because any company that can sustain growing payouts for a long time likely has a strong underlying business. It's even better to invest in excellent income stocks when they seem to be trading at attractive valuations, which isn't always easy to find since such corporations are in high demand.
Positive
Seeking Alpha
about 16 hours ago
Inflation can be countered by investing in income-generating assets like consumer staples, energy, and pharmaceuticals, which provide essential products and reliable dividends. In this article, I highlight two such names that offer robust payouts which are well-covered by earnings. Both carry moat-worthy business models and have strong pipelines that support potential for robust total returns.
Positive
Reuters
one day ago
AbbVie said that the U.S. Food and Drug Administration approved its drug for complicated intra-abdominal infections on Friday.
More AbbVie News

Company Profile

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease; metabolic diseases, comprising thyroid disease and complications associated with cystic fibrosis; pain associated with endometriosis; and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Head office United States
CEO Robert Michael
Founded 2011
Website www.abbvie.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today